quest-diagnostics-clinical-laboratories Research by SuperAGI

Quest Diagnostics Incorporated

Ticker Symbol: DGX

Headquarters: Secaucus, New Jersey, USA

Industry: Healthcare – Diagnostic Information Services

Employees: Approximately 56,000

Fiscal Year-End: December 31

Stock Exchange: New York Stock Exchange

Market Capitalization: $21.22 billion

Revenue (2025): Approximately $11.04 billion

Net Income (2025): Data not specified

Assets (2025): Data not specified

Equity (2025): Data not specified

Earnings Per Share (EPS): $8.52

Price-to-Earnings (P/E) Ratio: 21.90

Beta: 0.66 (indicating 34% less volatility than the S&P 500)

Institutional Ownership: 88.1%

Insider Ownership: 8.2%

Competitors: Laboratory Corporation of America Holdings (Labcorp), Henry Schein, Medpace, AMN Healthcare Services, DaVita

Background

Quest Diagnostics Incorporated is a leading provider of diagnostic information services, offering a comprehensive range of laboratory testing solutions. The company serves approximately one in three adult Americans and half the physicians and hospitals in the United States annually. Quest Diagnostics operates nationwide, providing diagnostic insights that aid in disease identification, treatment, and healthcare management.

Key Strategic Focus

Quest Diagnostics focuses on delivering a broad spectrum of diagnostic testing services, including routine, non-routine, and advanced clinical testing, as well as anatomic pathology testing. The company emphasizes innovation in diagnostic solutions, leveraging its extensive database to develop new tests and improve healthcare outcomes. Key areas of specialization include:

Cancer Diagnostics: Advanced genomic tests for cancer detection and monitoring.

Cardiometabolic and Endocrine Testing: Assessments for heart disease, diabetes, and other chronic conditions.

Infectious Disease Testing: Services for diseases such as COVID-19, tuberculosis, and tick-borne illnesses.

Neurology Diagnostics: Testing related to neurological disorders, including Alzheimer's disease.

Workplace Drug Testing: Services for employers to ensure a safe and compliant workforce.

Financials and Funding

Quest Diagnostics is a publicly traded company on the New York Stock Exchange under the ticker symbol DGX. The company reported revenues of approximately $11.04 billion in 2025. Specific details regarding net income, assets, equity, and funding history are not specified in the available sources.

Pipeline Development

While specific pipeline candidates and clinical trial stages are not detailed in the available sources, Quest Diagnostics is known for its continuous development of diagnostic tests across various medical fields. The company invests in research and development to introduce innovative testing solutions that address emerging health concerns and improve patient care.

Technological Platform and Innovation

Quest Diagnostics leverages advanced technologies and scientific methodologies to enhance its diagnostic services:

Proprietary Technologies: Development of in vitro diagnostic tests and laboratory diagnostic information systems.

Scientific Methods: Utilization of advanced genomic testing, molecular diagnostics, and digital health connectivity systems.

AI-Driven Capabilities: Integration of artificial intelligence in data analysis to improve diagnostic accuracy and efficiency.

Leadership Team

James E. Davis: Chairman, Chief Executive Officer, and President. James Davis has been with Quest Diagnostics since 2004, serving in various leadership roles, including Chief Financial Officer and Executive Vice President. He became CEO in 2012 and has been instrumental in the company's growth and strategic direction.

Sam A. Samad: Executive Vice President and Chief Financial Officer. Samad joined Quest Diagnostics in 2013, bringing extensive experience in financial management and strategic planning.

Michael E. Prevoznik J.D.: Senior Vice President and General Counsel. Prevoznik has been with Quest Diagnostics since 2007, overseeing legal affairs and corporate governance.

Catherine T. Doherty: Executive Vice President of Regional Businesses. Doherty joined the company in 2014, focusing on expanding Quest Diagnostics' regional operations and partnerships.

Karthik Kuppusamy Ph.D.: Senior Vice President of Clinical Solutions. Kuppusamy has been with Quest Diagnostics since 2015, leading the development of clinical testing services and solutions.

Michael J. Deppe: Senior Vice President, Corporate Controller, and Chief Accounting Officer. Deppe joined the company in 2016, managing financial reporting and accounting functions.

Murali Balakumar: Senior Vice President and Chief Information and Digital Officer. Balakumar has been with Quest Diagnostics since 2017, overseeing information technology and digital strategy.

Kristin Lee Wallace Esq.: Senior Vice President and Chief Compliance Officer. Wallace joined the company in 2018, ensuring compliance with regulatory requirements and ethical standards.

Garry Clark: Senior Vice President and Chief Marketing and Communications Officer. Clark has been with Quest Diagnostics since 2019, leading marketing and communications initiatives.

Cecilia K. McKenney: Senior Vice President and Chief Human Resources Officer. McKenney joined the company in 2020, focusing on talent management and organizational development.

Competitor Profile

Market Insights and Dynamics:

The diagnostic information services market is characterized by rapid technological advancements, increasing demand for personalized medicine, and a growing emphasis on preventive healthcare. The market is competitive, with several key players offering a range of diagnostic testing services.

Competitor Analysis:

Laboratory Corporation of America Holdings (Labcorp): A leading global life sciences company providing comprehensive clinical laboratory services, including routine and specialized testing.

Henry Schein: A global distributor of medical, dental, and veterinary supplies, offering diagnostic testing services through its network.

Medpace: A full-service clinical contract research organization providing outsourced services to the pharmaceutical, biotechnology, and medical device industries.

AMN Healthcare Services: A healthcare workforce solutions company offering staffing and workforce management services, including diagnostic testing personnel.

DaVita: A healthcare company specializing in kidney care and dialysis services, with a focus on patient care and clinical outcomes.

Strategic Collaborations and Partnerships

Quest Diagnostics has established various collaborations and partnerships to enhance its service offerings and market reach. Notable collaborations include:

Safeway Partnership (2016): Quest Diagnostics collaborated with Safeway to provide testing services in select Safeway stores across multiple states.

Walmart Partnership (2017): The company partnered with Walmart to offer laboratory testing in Walmart locations in Texas and Florida.

UnitedHealthcare Agreement (2018): Quest Diagnostics became an in-network laboratory provider to UnitedHealthcare, providing access to 48 million plan members.

Operational Insights

Quest Diagnostics maintains a strong market position through its extensive laboratory network, comprehensive test menu, and commitment to innovation. The company's operational strengths include:

Nationwide Laboratory Network: A vast network of laboratories and patient service centers ensuring broad access to diagnostic testing services.

Comprehensive Test Menu: Offering over 3,000 tests, including advanced genomic tests for cancer and rare diseases.

Innovation in Diagnostics: Continuous development of new tests and services to meet evolving healthcare needs.

Strategic Opportunities and Future Directions

Quest Diagnostics is well-positioned to capitalize on several strategic opportunities:

Expansion of Consumer-Directed Testing: Growth in direct-to-consumer testing services, allowing patients to access health information conveniently.